Close menu




February 17th, 2021 | 10:39 CET

Cardiol Therapeutics, Formycon, Teva Pharmaceuticals: COVID in focus!

  • Biotechnology
Photo credits: pixabay.com

According to recent statistics from the WHO, nowhere is research currently more intense than in the area of viral diseases. At least 248 vaccine projects have been initiated against COVID-19 since January 2020, but only the research projects have already been reported. But of course, we humans do not only fall ill from flu viruses and their dangerous mutants, but the permanent change in our lives alone intensifies diseases that arise from lack of exercise and contact and sometimes cause worse consequences than a flu-like effect. Everyone is currently looking to hopeful vaccine solutions, but several biotech and pharmaceutical companies can still make us healthier with new developments.

time to read: 3 minutes | Author: André Will-Laudien
ISIN: CA14161Y2006 , DE000A1EWVY8 , US8816242098

Table of contents:


    Cardiol Therapeutics - Many ideas in the quiver

    One troublesome combination is the combination of flu-like infections and inflammatory-related heart conditions, e.g., myocarditis. Cardiol Therapeutics is a Canadian pharmaceutical Company that has a potential answer to treating both heart complications due to COVID-19 and inflammatory heart disease. It involves the administration-friendly oral delivery of a proprietary CBD compound, CardiolRx™, to reduce inflammation. In this context, Cardiol works with appropriately high doses, which have already shown promising results in various test series, and a clinical phase 1 has already been completed.

    A fascinating area of research for Cardiol is also "acute myocarditis." Acute myocarditis is the most common cause of sudden cardiac death in people under 35 years of age. The latest data from the Global Burden of Disease Study suggests that the prevalence of acute myocarditis is about 22 per 100,000 population. Some cardiologists have already taken a closer look, and Berlin's Charité Hospital is also on the list.

    In the US and the European Union, compounds for rare diseases are eligible for accelerated marketing approval. There are other incentives, such as extended market exclusivity, to launch the resulting drug properly. Smaller companies often fail to do this because of the availability of appropriate investment budgets throughout the development timeline. This is not the case with Cardiol Therapeutics. So far, the Company has been able to refinance itself well, and the share price of CAD 4.80 at the beginning of 2021 was just below the high from 2020. In our opinion, the Company's attractiveness lies in the diversity and flexibility of the research topics, especially for current complexes of topics.

    Formycon - The biosimilar expert shows muscles

    Six weeks ago, biosimilar manufacturer Formycon drew attention with an application against COVID-19. A SARS-CoV-2 blocker developed by the Company, called FYB207, could completely prevent cells from becoming infected. SARS-CoV-2 and other coronaviruses use the receptor ACE2 on the surface of human cells as their main port of entry. Formycon's ACE2 antibody fusion protein effectively binds to SARS coronaviruses at precisely this point. At the time, the share price went through the roof, rising from EUR 36 to EUR 72, before consolidating to below EUR 55. Now the cards are being reshuffled.

    The current share price development shows that the market at Formycon is currently carrying out a revaluation. The Covid-19 drug candidate FYB207 is again in focus. Should the production of the substance in large quantities work out faster than expected, analysts see a blockbuster potential of billions. That's because vaccinations are delayed and there is not yet sufficient evidence to determine whether mutants can be appropriately "vaccinated away." Formycon's drug alters the surface of the cells, preventing any flu viruses from docking. This is a unique approach to date.

    In the second half of 2021, we believe that a clinical phase may already be underway. In turn, it could be that after successful market approval, another COVID drug can be used as standard therapy. The analysts at Nord LB raised their price target from EUR 45 to EUR 80 for the time being; the share was trading at EUR 72 yesterday. Still very interesting!

    Teva Pharmaceuticals - Long forgotten, now interesting again

    Teva Pharmaceutical Industries Limited is an Israeli pharmaceutical Company that operates globally and is considered the world leader in generic pharmaceuticals. The group is active in over 70 countries and generated nearly USD 17 billion in global sales in 2020 with almost 57,000 employees. Teva specializes in the development, production and distribution of pharmaceuticals such as specialty therapeutics, generics and over-the-counter medicines.

    Teva has been worried about its capital structure for the past 2 years, with debt widely considered too high at USD 13.2 billion. Teva Pharmaceutical Industries Limited reported Q4 2020 earnings of USD 0.68 per share, beating analyst estimates of USD 0.62. Revenues rose 10% year on year, driven by higher operating income and a lower tax rate.

    The generic drug maker's sales totaled USD 4.45 billion in the quarter, beating the consensus estimate of USD 4.36 billion. The pandemic led to lower demand for some products due to reduced activity by physicians and hospitals, primarily in North America. However, demand for some products related to the treatment of COVID-19 symptoms continued to increase.

    Teva's share price made a low of below USD 5 in August 2019 and recovered to a stable USD 11 by 2021. Chart-wise, things are now getting exciting as a long-standing resistance at USD 13 is looming. However, the current market momentum is currently in favor of investing in pharmaceutical companies, which should support the positive trend for Teva. Collect cautiously!


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST

    Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

    • Biotechnology

    Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.

    Read